Kobay Technology Berhad Q3 FY2026 Results: Strong Growth Across All Divisions
Key Highlights for Investors
- Revenue surged 78% YoY for Q3 FY2026 to RM145.0 million, while profit before tax (PBT) soared by 6807% to RM17.06 million.
- 9-month revenue increased by 56% to RM400.9 million; PBT up 255% to RM48.2 million.
- Significant improvements in all major business segments: Manufacturing, Property Development, Pharmaceutical & Healthcare, and Asset Management & Investment Holding.
- Basic earnings per share (EPS) jumped to 4.40 sen for the quarter and 11.42 sen for 9 months, up from 0.22 sen and 3.18 sen respectively.
- No dividend declared for the quarter.
- Net assets per share rose to RM1.24 from RM1.12 at financial year-end.
- Group borrowings decreased to RM123.4 million (from RM131.0 million previously).
- Strong cash flow from operations: RM72.0 million for the 9 months ended 31 March 2026.
- Major customer dependency: One customer contributed more than 10% of group revenue—a potential risk and opportunity.
Detailed Segment Performance
Manufacturing
- Q3 revenue up 89% YoY to RM97.5 million; PBT up 461% to RM9.82 million.
- 9-month revenue up 64% YoY to RM269.7 million; 9-month PBT up 183% to RM32.9 million.
- Growth driven primarily by increased sales orders, especially in the E&E industry.
- Management expects continued rebound, with strategic expansion planned into the Electronics Manufacturing Services (EMS) sector. Efficiency and cost optimization initiatives are also underway.
Property Development
- Q3 revenue up 144% YoY to RM15.8 million; PBT up 775% to RM2.12 million.
- 9-month revenue up 166% to RM39.6 million; 9-month PBT up 399% to RM4.62 million.
- Driven by progress billing from ongoing affordable housing projects and sale of completed units.
- Contribution expected to remain positive, but management is cautious about rising construction costs and interest rates. New launches to be timed with market sentiment.
Pharmaceutical & Healthcare
- Q3 revenue up 22% YoY to RM20.5 million; PBT up 222% to RM1.82 million.
- 9-month revenue up 6% to RM60.9 million; 9-month PBT up 97% to RM4.81 million.
- Performance supported by higher-margin products and new medical device launches.
- Management expects steady future demand, but notes potential headwinds from higher living costs. Strategy includes expanding product range and exploring overseas markets.
Asset Management & Investment Holding
- Q3 revenue up 73% YoY to RM11.2 million; PBT up 892% to RM1.94 million.
- 9-month revenue up 49% to RM30.3 million; 9-month PBT up 720% to RM5.53 million.
- Boosted by higher hotel revenue during the peak holiday season.
Financial Position and Liquidity
- Total assets increased to RM709.9 million (from RM621.8 million at year-end).
- Equity attributable to owners rose to RM395.9 million.
- Net cash from operating activities: RM72.0 million, a major turnaround from RM1.3 million in the same period last year.
- Capital commitments: RM2.56 million for property, plant and equipment contracted but not provided for.
- Cash & cash equivalents: RM34.9 million at end-Q3, down from RM43.6 million a year earlier, but with strong highly liquid investments.
Other Important Information for Shareholders
- No dividends declared or paid during the period under review.
- No new borrowings or equity issues during the quarter.
- No material litigation or contingent liabilities as of the reporting date.
- The group’s operations are cyclical, primarily exposed to the global electronics industry and real estate market volatility.
- One major customer accounted for more than 10% of group revenue—a concentration risk to monitor.
- No profit forecast or guarantee was issued for the current period.
- Taxation: Effective tax rate higher than statutory due to losses in some subsidiaries not offsettable against group profits.
- No unusual items or significant estimates affecting the results.
- No material subsequent events or changes in group composition post-quarter.
Outlook and Prospects
- Management maintains a cautiously optimistic outlook for FY2026, expecting further improvement in manufacturing as the global economy recovers.
- Property segment contribution expected to remain positive, but management remains vigilant regarding costs and market timing.
- Pharmaceutical & healthcare to focus on product expansion and cost control to offset potential demand challenges from rising living costs.
- Asset management expected to benefit from continued hotel recovery, but overall group strategy remains prudent amid potential recessionary risks and cost pressures.
Potential Price-Sensitive Issues
- Massive YoY earnings growth (EPS up ~20x, PBT up ~26x for Q3) could trigger significant investor interest and potentially move the share price.
- Strong cash generation and improved financial position may support future dividend payments or growth investments.
- Customer concentration risk: The reliance on one major customer may pose both opportunity and risk, depending on that customer’s future orders.
- No dividend declared might disappoint yield-focused investors despite strong profits.
- Sectoral recovery in manufacturing and strategic EMS expansion could drive future earnings.
Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell shares in Kobay Technology Berhad. Investors should perform their own due diligence and consult professional advisors before making investment decisions.
Versi Bahasa Malaysia
Keputusan Suku Ketiga FY2026 Kobay Technology Berhad: Pertumbuhan Kukuh dalam Semua Segmen
Perkara Utama untuk Pelabur
- Pendapatan melonjak 78% YoY untuk S3 FY2026 kepada RM145.0 juta, manakala untung sebelum cukai (PBT) melonjak 6807% kepada RM17.06 juta.
- Pendapatan 9 bulan meningkat 56% kepada RM400.9 juta; PBT naik 255% kepada RM48.2 juta.
- Peningkatan ketara dalam semua segmen utama perniagaan: Pembuatan, Pembangunan Hartanah, Farmaseutikal & Penjagaan Kesihatan, dan Pengurusan Aset & Pegangan Pelaburan.
- Pendapatan sesaham (EPS) asas melonjak kepada 4.40 sen untuk suku tersebut dan 11.42 sen untuk 9 bulan, berbanding 0.22 sen dan 3.18 sen sebelum ini.
- Tiada dividen diisytiharkan untuk suku tahun ini.
- Aset bersih sesaham meningkat kepada RM1.24 daripada RM1.12 pada akhir tahun kewangan.
- Pinjaman kumpulan berkurang kepada RM123.4 juta (daripada RM131.0 juta sebelum ini).
- Aliran tunai operasi kukuh: RM72.0 juta untuk 9 bulan berakhir 31 Mac 2026.
- Ketergantungan kepada pelanggan utama: Seorang pelanggan menyumbang lebih 10% daripada pendapatan kumpulan—risiko dan peluang untuk dipantau.
Prestasi Segmen Secara Terperinci
Pembuatan
- Pendapatan S3 naik 89% YoY kepada RM97.5 juta; PBT naik 461% kepada RM9.82 juta.
- Pendapatan 9 bulan naik 64% YoY kepada RM269.7 juta; PBT 9 bulan naik 183% kepada RM32.9 juta.
- Peningkatan didorong oleh pesanan jualan yang lebih tinggi, terutamanya dalam industri E&E.
- Pengembangan strategik ke sektor EMS dan penambahbaikan kecekapan pengeluaran sedang dilaksanakan.
Pembangunan Hartanah
- Pendapatan S3 naik 144% YoY kepada RM15.8 juta; PBT naik 775% kepada RM2.12 juta.
- Pendapatan 9 bulan naik 166% kepada RM39.6 juta; PBT 9 bulan naik 399% kepada RM4.62 juta.
- Disokong oleh pengebilan kemajuan projek perumahan mampu milik dan penjualan unit siap.
- Sumbangan dijangka kekal positif, tetapi pengurusan berhati-hati terhadap kenaikan kos dan kadar faedah.
Farmaseutikal & Penjagaan Kesihatan
- Pendapatan S3 naik 22% YoY kepada RM20.5 juta; PBT naik 222% kepada RM1.82 juta.
- Pendapatan 9 bulan naik 6% kepada RM60.9 juta; PBT 9 bulan naik 97% kepada RM4.81 juta.
- Prestasi disokong oleh produk margin tinggi dan pelancaran peranti perubatan baharu.
- Jangkaan permintaan stabil akan datang, strategi pengembangan produk dan kawalan kos diteruskan.
Pengurusan Aset & Pegangan Pelaburan
- Pendapatan S3 naik 73% YoY kepada RM11.2 juta; PBT naik 892% kepada RM1.94 juta.
- Pendapatan 9 bulan naik 49% kepada RM30.3 juta; PBT 9 bulan naik 720% kepada RM5.53 juta.
- Didorong oleh peningkatan hasil hotel semasa musim cuti puncak.
Kedudukan Kewangan & Kecairan
- Jumlah aset meningkat kepada RM709.9 juta (daripada RM621.8 juta pada akhir tahun).
- Ekuiti pemilik meningkat kepada RM395.9 juta.
- Aliran tunai operasi: RM72.0 juta, perubahan besar daripada RM1.3 juta tahun lalu.
- Komitmen modal: RM2.56 juta untuk aset yang telah dikontrakkan tetapi belum diiktiraf.
- Tunai & setara tunai: RM34.9 juta pada akhir S3.
Perkara Penting untuk Pemegang Saham
- Tiada dividen diisytiharkan atau dibayar sepanjang tempoh.
- Tiada pengeluaran hutang atau ekuiti baharu semasa suku ini.
- Tiada litigasi material atau liabiliti luar jangka semasa tarikh laporan.
- Perniagaan bersifat kitaran, terdedah kepada turun naik industri elektronik global dan hartanah.
- Ketergantungan kepada satu pelanggan utama merupakan risiko tumpuan yang perlu dipantau.
- Tiada ramalan keuntungan dikeluarkan untuk tempoh semasa.
- Kadar efektif cukai lebih tinggi kerana kerugian beberapa subsidiari tidak boleh diimbangi dengan keuntungan kumpulan.
- Tiada perkara luar biasa atau perubahan ketara dalam anggaran.
- Tiada peristiwa material selepas suku atau perubahan besar dalam komposisi kumpulan.
Prospek
- Pengurusan kekal optimistik berhati-hati untuk FY2026, jangkaan pemulihan berterusan dalam pembuatan.
- Segmen hartanah dijangka kekal positif, tetapi pengurusan teliti terhadap kos dan masa pasaran.
- Farmaseutikal & penjagaan kesihatan fokus pada pengembangan produk dan kawalan kos untuk menampan cabaran kos sara hidup yang tinggi.
- Pengurusan aset dijangka terus pulih, namun strategi kumpulan kekal berwaspada terhadap risiko kemelesetan dan tekanan kos.
Faktor Sensitif Harga
- Pertumbuhan keuntungan YoY yang luar biasa (EPS naik ~20x, PBT naik ~26x untuk S3) berpotensi menarik minat pelabur dan menggerakkan harga saham.
- Penjanaan tunai yang kukuh dan kedudukan kewangan yang bertambah baik boleh menyokong pembayaran dividen atau pelaburan masa depan.
- Risiko tumpuan pelanggan: Ketergantungan kepada satu pelanggan utama boleh menjadi peluang atau risiko, bergantung pada pesanan masa depan pelanggan tersebut.
- Tiada dividen diisytiharkan mungkin mengecewakan pelabur berorientasi hasil walaupun keuntungan kukuh.
- Pemulihan sektor pembuatan dan pengembangan EMS strategik boleh memacu pendapatan masa depan.
Penafian: Artikel ini hanya untuk tujuan makluman dan bukan nasihat kewangan atau cadangan untuk membeli atau menjual saham Kobay Technology Berhad. Pelabur dinasihatkan membuat penilaian sendiri dan mendapatkan nasihat profesional sebelum membuat keputusan pelaburan.
